Peng Yuan,Xiao-Hong He,Ye-Fei Rong,Jing Cao,Yong Li,Yun-Ping Hu,Yingbin Liu,Dangsheng Li,Wenhui Lou,Mo-Fang Liu

Abstract:This file contains Materials and Methods that are involved in the figures of the main text and supplementary information. These materials and methods include information of plasmid constructs, cell transfection and viral transduction, RNA preparation and qRT-PCR, luciferase reporter assay, ChIP assay, therapeutic experiments in mice, and immunohistochemistry and in situ hybridization.

Supplementary Materials and Methods from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Table 1 from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Table 4 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Methods and References from MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial–Mesenchymal Transition and Metastasis in Colorectal Cancer

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Materials and Methods and Supplementary Figure Legends from Mir200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer

Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Figure S1, Table S1, Table S2 from KLF4 P.a472d Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>bap1</i> and <i>setd2</i>: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Materials and Methods from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in &Lt;i>pik3ca</i>-Mutant Colorectal Cancer

Supplementary Materials from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Data from CSN6 Mediates Nucleotide Metabolism to Promote Tumor Development and Chemoresistance in Colorectal Cancer

Supplementary Materials and Methods from RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo–Yap Pathway

Additional File 4: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Additional File 1: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Supplementary Methods and Materials, Figure Legend from ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM

Supplemental materials from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Materials and Methods from &lt;i&gt;pik3ca&lt;/i&gt; Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Table 1 from &lt;i&gt;pik3ca&lt;/i&gt; Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer